<DOC>
	<DOC>NCT00997477</DOC>
	<brief_summary>This study will evaluate the correct use of sequential formoterol and budesonide inhaler capsule treatment via Aerolizer and patient satisfaction in adult asthmatics.</brief_summary>
	<brief_title>Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Moderate persistent asthmatic patients. No previous Aerolizer experience. Lifethreatening asthma: A subject must not have lifethreatening asthma as a history of significant asthma episode(s)requiring intubation associated with hypercapnia, respiratory arrest or hypoxic seizures, or asthmarelated syncopal episode(s). Worsening of asthma: A subject must not have experienced a worsening of asthma which involved a hospitalization within 6 months of screening, or an emergency room visit three or more times in the past 6 months, or use of oral corticosteroids for worsening asthma within 3 months of screening. Unstable asthma: During screening period, a patient requires the use of &gt;8 puffs/day of salbutamol 100 mcg per actuation pMDI on two consecutive days. A subject must not have had an upper respiratory tract infection within 4 weeks of screening. FEV1&lt; 60% at screening. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>aerolizer</keyword>
	<keyword>formoterol</keyword>
	<keyword>budesonide</keyword>
	<keyword>asthma</keyword>
</DOC>